Country: Իռլանդիա
language: անգլերեն
source: HPRA (Health Products Regulatory Authority)
Bicalutamide
Fairmed Healthcare GmbH
L02BB; L02BB03
Bicalutamide
50 milligram(s)
Film-coated tablet
Product subject to prescription which may not be renewed (A)
Anti-androgens; bicalutamide
Not marketed
2012-09-14
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT _ _ BICALUTAMIDE FAIR-MED 50 MG FILM-COATED TABLETS Bicalutamide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects ,talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. _ _ WHAT IS IN THIS LEAFLET 1. What Bicalutamide Fair-Med is and what it is used for 2. What you need to know before you take Bicalutamide Fair-Med 3. How to take Bicalutamide Fair-Med 4. Possible side effects 5. How to store Bicalutamide Fair-Med 6. Contents of the pack and other information 1. WHAT BICALUTAMIDE FAIR-MED IS AND WHAT IT IS USED FOR Bicalutamide Fair-Med contains a medicine called bicalutamide. This belongs to a group of medicines called ‘anti-androgens’. It works by blocking the effect of the male sex hormones (androgens) and inhibits cell growth in the prostate. Bicalutamide Fair-Med is used to treat advanced prostate cancer. It is taken together with an additional hormone treatment (called LHRH analogue) or with accompanying surgical removal of the testicles. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BICALUTAMIDE FAIR-MED DO NOT TAKE BICALUTAMIDE FAIR-MED: if you are allergic to bicalutamide or any of the other ingredients of this medicine (listed in Section 6). if you are already taking a medicine called cisapride or certain anti-histamine medicines (terfenadine or astemizole). if you are a woman. Do not take Bicalutamide Fair-Med if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Bicalutamide Fair-Med. Bicalutamide Fair-Med must not be given to children and adolescents. WARNINGS AND PRECAUTIONS Talk read_full_document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Bicalutamide Fair-Med 50mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg Bicalutamide Excipient(s) with known effect: Each tablet contains 62.7 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White, round, biconvex, film coated tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Bicalutamide Fair-Med is indicated for the treatment of advanced prostate cancer in combination with LHRH analogue therapy or surgical castration. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adult males including the elderly: one tablet (50 mg) once a day. Route: Oral use. The tablets should be swallowed whole with liquid. Treatment with Bicalutamide Fair-Med should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration. Children and adolescents: Bicalutamide Fair-Med is contraindicated in children and adolescents. Renal impairment: No dosage adjustment is necessary for patients with renal impairment. There is no experience with the use of bicalutamide in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see Section 4.4). Hepatic impairment: No dosage adjustment is necessary for patients with mild hepatic impairment. Increased accumulation may occur in patients with moderate to severe hepatic impairment (see section 4.4). 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Bicalutamide Fair-Med is contraindicated in females, children and adolescents (see section 4.6). Co-administration of terfenadine, astemizole or cisapride with bicalutamide is contraindicated (see section 4.5). 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Initiation of treatment should be under the direct supervision of a specialist and subsequently patients should be kept under regular surveillance. Bicalutamide is extensively metabolised read_full_document